Kite Pharma, a California-based biotech focused on developing novel cancer immunotherapies, secured $20 million in its latest funding round. Kite has access to the National Cancer Institute's pipeline of engineered autologous peripheral blood T cells that can be targeted to multiple hematological and solid tumor types.
Calif. biotech startup gets $20M funding boost
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||